Endocrine Abstracts

Transsphenoidal surgery still appears to be the best option for most of the patients with GH secreting adenomas. In many cases the biochemical cure targets are not reached and the patient needs adjuvant therapy. Alternatives include medical therapy with somatostatin analogues, GH-receptor antagonists and dopamine agonists. These drugs can be used alone or in combination. Radiation therapy with conventional fractionated photons or radiosurgery with proton beam could also be eff...

Introduction: GH therapy (rhGH) improves growth outcome in children born small for gestational age (SGA). Growth velocity is maximum in the first year of therapy. Early diagnosis and treatment optimizes the final height.Objectives: Evaluation of efficacy and safety profile in the first 3 years of rhGH treatment in ten SGA children.Methods: The study enrolled ten SGA children (6 boys, 4 girls). All patients were given a mean dose of...

Introduction: Growth hormone (rhGH) is an effective treatment for short children born small for gestational age (SGA) who fail to demonstrate catch-up growth by 2–4 years of age. This children usually do not have classical GH deficiency, but either low GH secretion or reduced sensitivity to GH. The goals of therapy are to achieve a normal height in early childhood and an adult height within the normal target range.Objectives: Evaluation of efficacit...

Introduction: The most common cause of Cushing’s disease is ACTH secreting tumours of the pituitary gland. It is associated with high morbidity and mortality. Pasireotide, a potential therapy, has a unique, broad somatostatin-receptor–binding profile, with high binding affinity for somatostatin-receptor subtype 5.Case report: We present the a 40-years-old man diagnosed in 2005 with Cushing’s Disease for which a left adrenalectomy was perfo...